| | 698387-09-6 Basic information More.. |
| Product Name: | Neratinib | | Synonyms: | Neratinib(HKI-272);(2E)-N-[4-[[3-chloro-4-(2-pyridinylMethoxy)phenyl]aMino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(diMethylaMino)-2-butenaMide;neratinib;(E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;Unii-jjh94R3pwb;(2e)-n-(4-((3-chloro-4-((pyridin-2-yl)Methoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(diMethylaMino)but-2-enaMide neratinib;HKI-272 Neratinib | | CAS: | 698387-09-6 | | MF: | C30H29ClN6O3 | | MW: | 557.04 | | EINECS: | 811-237-1 | | Mol File: | 698387-09-6.mol |  |
Use
Neratinib developed by US Wyeth company is an irreversible epidermal growth factor receptor(EGFR) inhibitor. It is a multiple target point of small molecule tyrosine kinase inhibitors to HER 2 and HER1 after Lapatinib, and is an irreversible ErbB receptor tyrosine kinase inhibitor. Neratinib could selectively inhibit HER-1 and HER-2 of EGFR family(IC50 was 92 nmol/L and 59 nmol/L, respectively). Clinical research showed that Neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer.
The phaseⅡclinical trial indicated that Neratinib showed good efficacy and tolerance to HER-2 positive patients with advanced breast cancer who had been received or not Trastuzumab treatment.
The phase Ⅲ breast cancer clinical trial was complete in September 2014. The data indicated that the efficacy of Neratinib was better than Roche's Herceptin in treatment of HER-2 positive early breast cancer.
The above information is edited by the Chemicalbook of Liu Yujie.
- Neratinib
-
- US $0.00-0.00 / kg
- 2025-04-04
- CAS:698387-09-6
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- Neratinib
-
- US $0.00-0.00 / kg
- 2024-11-26
- CAS:698387-09-6
- Min. Order: 1kg
- Purity: 99%，single impurity＜0.1
- Supply Ability: 1 ton
- Neratinib
-
- US $30.00-64.00 / mg
- 2024-11-19
- CAS:698387-09-6
- Min. Order:
- Purity: 98.55%
- Supply Ability: 10g
|
|
698387-09-6
Recommend Suppliers |
|